SK Bioscience Reports Operating Profit of 115 Billion KRW Last Year, Down 76% YoY

[Asia Economy Reporter Myunghwan Lee] SK Bioscience announced on the 8th that its consolidated operating profit for last year was tentatively estimated at 115 billion KRW, down 75.7% compared to the same period last year.

During the same period, sales decreased by 50.8% to 456.7 billion KRW, and net profit fell by 65.5% to 122.5 billion KRW.

SK Bioscience explained the cause of the poor performance as "the impact of decreased sales from contract manufacturing (CMO) and contract development and manufacturing (CDMO) of COVID-19 vaccines."

On the same day, SK Bioscience resolved to establish the 'Songdo Global R&PD Center' and decided to make an investment of 325.7 billion KRW. This is the largest investment since its launch.